3,644,530 4,896,607 5,661,077
Other revenues 198,592 1,505,737 945,286 2,761,069
Total Net Revenues 13,631,729 19,385,612 25,456,016 31,094,789
COST OF SALES 5,743,166 9,696,718 10,929,324 17,465,143
GROSS PROFIT 7,888,563 9,688,894 14,526,692 13,629,646
OPERATING EXPENSES:
Selling expenses 1,801,235 5,875,549 3,503,034 6,997,886
Research and
development -- 471,243 -- 1,181,468
General and
administrative 769,103 542,043 1,516,309 1,168,460
Total Operating
Expenses 2,570,338 6,888,835 5,019,343 9,347,814
INCOME FROM OPERATIONS 5,318,225 2,800,059 9,507,349 4,281,832
OTHER INCOME
(EXPENSE):
Debt issuance
costs (99,516) (99,517) (199,033) (162,403)
Interest income 44,793 2,027 46,112 2,588
Interest expense (470,551) (522,660) (918,648) (946,009)
Total Other Income
(Expense) (525,274) (620,150) (1,071,569) (1,105,824)
INCOME BEFORE INCOME
TAXES 4,792,951 2,179,909 8,435,780 3,176,008
INCOME TAXES 7,418 -- 82,145 --
NET INCOME $4,785,533 $2,179,909 $8,353,635 $3,176,008
COMPREHENSIVE INCOME:
NET INCOME 4,785,533 2,179,909 8,353,635 3,176,008
OTHER
COMPREHENSIVE
INCOME:
Unrealized foreign
currency
translation gain 2,896 1,587,538 65,007 3,041,741
COMPREHENSIVE
INCOME $4,788,429 $3,767,447 $8,418,642 $6,217,749
NET INCOME PER COMMON
SHARE:
Basic
'/>"/>SOURCE Lotus Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets2.
Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue3.
Lotus Pharmaceuticals Announces Second Quarter 2008 Results4.
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results5.
Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results6.
Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT7.
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 20098.
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results9.
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT10.
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States11.
Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement